Latest & greatest articles for celecoxib

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on celecoxib or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on celecoxib and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for celecoxib

41. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. 15713944 2005 03 23 2005 03 28 2015 11 19 1533-4406 352 11 2005 Mar 17 The New England journal of medicine N. Engl. J. Med. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. 1071-80 Selective cyclooxygenase-2 (COX-2) inhibitors have come under scrutiny because of reports suggesting an increased cardiovascular risk associated with their use (...) . Experimental research suggesting that these drugs may contribute to a prothrombotic state provides support for this concern. We reviewed all potentially serious cardiovascular events among 2035 patients with a history of colorectal neoplasia who were enrolled in a trial comparing two doses of celecoxib (200 mg or 400 mg twice daily) with placebo for the prevention of colorectal adenomas. All deaths were categorized as cardiovascular or noncardiovascular, and nonfatal cardiovascular events were categorized

NEJM2005

42. A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare choice population

A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare choice population A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare choice population A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib (...) and celecoxib among older patients with osteoarthritis and hypertension in a Medicare choice population Becker R V, Burke T A, McCoy M A, Trotter J P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of two alternative cyclooxygenase

NHS Economic Evaluation Database.2003

43. Costs and effectiveness of rofecoxib, celecoxib, and acetaminophen for preventing pain after ambulatory otolaryngologic surgery

Costs and effectiveness of rofecoxib, celecoxib, and acetaminophen for preventing pain after ambulatory otolaryngologic surgery Costs and effectiveness of rofecoxib, celecoxib, and acetaminophen for preventing pain after ambulatory otolaryngologic surgery Costs and effectiveness of rofecoxib, celecoxib, and acetaminophen for preventing pain after ambulatory otolaryngologic surgery Watcha M F, Issioui T, Klein K W, White P F Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three oral analgesic regimens for preventing pain after ambulatory surgery were examined. The regimens were acetaminophen (2 g), celecoxib (200 mg) and rofecoxib (50 mg). The drugs were administered 15 to 45 minutes before entering the operating room. Type

NHS Economic Evaluation Database.2003

44. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis

The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis Maetzel A, Krahn M, Naglie G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Cyclooxgenase 2 (COX-2) selective non-steroidal anti-inflammatory drugs (NSAIDs) were compared with standard NSAIDs. In particular, the COX-2 NSAIDs rofecoxib (25 mg four times daily) and celecoxib (100 or 200 mg twice daily) were compared with the standard NSAIDs naproxen (500 mg twice daily), ibuprofen (800 mg three times daily

NHS Economic Evaluation Database.2003

45. Single dose oral celecoxib for postoperative pain.

Single dose oral celecoxib for postoperative pain. BACKGROUND: Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor prescribed for the relief of chronic pain in osteoarthritis and rheumatoid arthritis. The drug is believed to be associated with fewer adverse effects than conventional non-steroidal anti-inflammatory drugs (NSAIDs). However, the effectiveness of celecoxib in the treatment of acute pain has not yet been assessed by systematic review. OBJECTIVES: To assess the analgesic (...) efficacy and adverse effects of a single oral dose of celecoxib for moderate to severe postoperative pain. SEARCH STRATEGY: We searched the Cochrane Library Controlled Trials Register, MEDLINE, Biological Abstracts, PubMed and the Oxford Pain database. Date of the most recent search: May 2002. SELECTION CRITERIA: Randomised controlled trials (RCTs) of adults prescribed any dose of oral celecoxib or placebo for acute postoperative pain were included. DATA COLLECTION AND ANALYSIS: Two trials (418

Cochrane2003

46. Fatal allergic vasculitis associated with celecoxib.

Fatal allergic vasculitis associated with celecoxib. We report on the occurrence of a rare and as yet unforseeable adverse reaction to treatment with celecoxib, a cyclooxygenase-2 (COX-2) selective, non-steroidal, anti-inflammatory drug. A previously healthy adult suffered fatal acute multiple organ failure presumably after diffuse allergic vasculitis with diffuse necrotic purpura. Although no conclusive proof is available, such a reaction could have been triggered by at least one of two (...) mechanisms: an allergic reaction linked to the chemical structure of celecoxib; or an interaction of the drug with synthesis of endothelial eiconasoids leading to an imbalance between vasoactive end products, resulting in widespread rise to local thrombosis.

Lancet2002

47. Economic assessment: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis

Economic assessment: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis Economic assessment: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis Economic assessment: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis Maetzel A, Krahn M, Naglie G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation Maetzel A, Krahn M, Naglie G. Economic assessment: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Technology Overview Issue 6. 2002 Authors' objectives The purpose of this assessment is to evaluate the long-term cost-effectiveness of the COX2 NSAID celecoxib, in comparison to diclofenac and ibuprofen, and rofecoxib in comparison to naproxen

Health Technology Assessment (HTA) Database.2002

48. The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis

The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis Maetzel A, Krahn M, Naglie G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Maetzel A, Krahn M, Naglie G. The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Technology Report No. 23. 2002 Authors' objectives The purpose of this assessment is to evaluate the long-term cost-effectiveness of the COX2 NSAIDs celecoxib, in comparison to diclofenac and ibuprofen, and rofecoxib in comparison to naproxen

Health Technology Assessment (HTA) Database.2002

49. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials

Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic (...) review of randomised controlled trials Deeks J J, Smith L A, Bradley M D Authors' objectives To determine the efficacy, gastrointestinal safety, and tolerability of celecoxib (a cyclo-oxygenase 2 inhibitor) used in the treatment of osteoarthritis and rheumatoid arthritis. Searching MEDLINE, EMBASE and the Cochrane Controlled Trials Register were searched from 1998 to 2001 using the search terms 'celecoxib', 'Celebrex' and 'SC-58635'. The authors also obtained the manufacturer reports for all industry

DARE.2002

50. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.

Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. 11754710 2001 12 28 2002 01 18 2016 10 17 0098-7484 287 1 2002 Jan 02 JAMA JAMA Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. 64-71 Osteoarthritis (OA) is often treated with nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or specific inhibitors of cyclooxygenase 2 (COX-2). To assess the relative therapeutic efficacy (...) of rofecoxib, celecoxib, and acetaminophen in adults with OA. Randomized, parallel-group, double-blind trial, conducted from June 1999 to February 2000, in 29 clinical centers in the United States. Three hundred eighty-two patients aged at least 40 years who had OA of the knee that was previously treated with NSAIDs or acetaminophen. Patients were randomly assigned to receive rofecoxib, 12.5 mg/d (n = 96); rofecoxib, 25 mg/d (n = 95); celecoxib, 200 mg/d (n = 97); or acetaminophen, 4000 mg/d (n = 94) for 6

JAMA2002

51. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. 12501222 2002 12 26 2003 01 02 2015 11 19 1533-4406 347 26 2002 Dec 26 The New England journal of medicine N. Engl. J. Med. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. 2104-10 Current guidelines recommend that patients at risk for ulcer disease who require treatment for arthritis receive (...) nonsteroidal antiinflammatory drugs (NSAIDs) that are selective for cyclooxygenase-2 or the combination of a nonselective NSAID with a proton-pump inhibitor. We assessed whether celecoxib would be similar to diclofenac plus omeprazole in reducing the risk of recurrent ulcer bleeding in patients at high risk for bleeding. We studied patients who used NSAIDs for arthritis and who presented with ulcer bleeding. After their ulcers had healed, we randomly assigned patients who were negative for Helicobacter pylori to receive either

NEJM2002

52. Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis

Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis National Institute (...) for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 27. 2001

Health Technology Assessment (HTA) Database.2001

53. Upper gastroduodenal ulceration in arthritis patients treated with celecoxib

Upper gastroduodenal ulceration in arthritis patients treated with celecoxib Upper gastroduodenal ulceration in arthritis patients treated with celecoxib Upper gastroduodenal ulceration in arthritis patients treated with celecoxib Ashcroft D M, Chapman S R, Clark W K, Millson D S Authors' objectives To evaluate the comparative incidence of endoscopic gastroduodenal ulcers in patients with rheumatoid arthritis or osteoarthritis, treated with celecoxib. Searching The Cochrane Controlled Trials (...) Register, MEDLINE and EMBASE were searched from 1988 to July 2000. The search terms included 'antiinflammatory agents, nonsteroidal', 'celecoxib', cycloxygenase inhibitors' and 'SC-58635'. The websites of the Food and Drug Administration, and the European Agency for the Evaluation of Medicinal Products, were also searched, together with the reference lists of the retrieved articles. Studies reported in any language were considered. Study selection Study designs of evaluations included in the review

DARE.2001

54. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland

Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland Chancellor J V M, Hunsche E, de Cruz E, Sarasin F P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of celecoxib (a cyclo-oxygenase 2 (COX-2) inhibitor) in the treatment of arthritis patients in Switzerland. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population A hypothetical population of 1000 patients with arthritis was studied. Both osteoarthritis (OA) and rheumatoid arthritis (RA) sufferers

NHS Economic Evaluation Database.2001

55. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. 10609815 2000 01 11 2000 01 11 2016 11 22 0140-6736 354 9196 1999 Dec 18-25 Lancet (London, England) Lancet Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. 2106-11 Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclo-oxygenase (COX), which leads to suppression of COX-1-mediated production of gastrointestinal (...) -protective prostaglandins. Gastrointestinal injury is a common outcome. We compared the efficacy, safety, and tolerability of long-term therapy with celecoxib, a COX-1 sparing inhibitor of COX-2, with diclofenac, a non-specific COX inhibitor. 655 patients with adult-onset rheumatoid arthritis of at least 6 months' duration were randomly assigned oral celecoxib 200 mg twice daily or diclofenac SR 75 mg twice daily for 24 weeks. Anti-inflammatory and analgesic activity and tolerability were assessed

Lancet2000

56. Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway

Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway Svarvar P, Aly A Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of celecoxib for the treatment of patients with osteoarthritis (OA) or rheumatoid arthritis (RA), in Norway. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population consisted

NHS Economic Evaluation Database.2000

57. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. 10874062 2000 06 29 2000 06 29 2015 11 19 0028-4793 342 26 2000 Jun 29 The New England journal of medicine N. Engl. J. Med. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. 1946-52 Patients with familial adenomatous polyposis have a nearly 100 percent risk of colorectal cancer. In this disease, the chemopreventive effects of nonsteroidal antiinflammatory drugs may (...) be related to their inhibition of cyclooxygenase-2. We studied the effect of celecoxib, a selective cyclooxygenase-2 inhibitor, on colorectal polyps in patients with familial adenomatous polyposis. In a double-blind, placebo-controlled study, we randomly assigned 77 patients to treatment with celecoxib (100 or 400 mg twice daily) or placebo for six months. Patients underwent endoscopy at the beginning and end of the study. We determined the number and size of polyps from photographs and videotapes

NEJM2000

58. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. 10979111 2000 09 21 2000 09 21 2016 10 17 0098-7484 284 10 2000 Sep 13 JAMA JAMA Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term (...) Arthritis Safety Study. 1247-55 Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1. Whether COX-2-specific inhibitors are associated with fewer clinical GI toxic effects is unknown. To determine whether celecoxib, a COX-2-specific inhibitor, is associated with a lower incidence of significant upper GI toxic effects and other adverse effects compared

JAMA2000

59. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. 10580457 1999 12 08 1999 12 08 2016 10 17 0098-7484 282 20 1999 Nov 24 JAMA JAMA Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. 1921-8 In vitro studies have shown that celecoxib inhibits cyclooxygenase 2 (COX-2) but not COX-1, suggesting that this drug may have anti-inflammatory and analgesic activity (...) without adverse upper gastrointestinal (GI) tract effects that result from COX-1 inhibition. To test whether celecoxib has efficacy as an anti-inflammatory and analgesic with reduced GI tract mucosal damage compared with conventional nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis. Randomized, multicenter, placebo-controlled, double-blind trial lasting 12 weeks, with follow-up at weeks 2, 6, and 12, from September 1996 thorugh February 1998. Seventy-nine clinical sites

JAMA1999